is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them antibiotics, antimalarials and cancer medicines. Roche has been recognised as the leading healthcare company in the Dow Jones Sustainability Indices since 2009.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. Roche invests around 10 billion US Dollars each year in research and development worldwide, including over AUD 37 million in pharmaceuticals in Australia. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Roche’s pharmaceutical division in Australia employs over 350 people who are dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to around 40 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.
For more information visit www.roche-australia.com